ImmunGen, which develops antibody-drug conjugates (ADCs) for the treatment of cancer, announced that it has amended its license agreements with Sanofi covering all compounds in development by Sanofi using ImmunoGen’s technology. Under the terms of the amended 2003 collaboration and license agreement, ImmunoGen has granted Sanofi a fully-paid, exclusive license to develop, manufacture, and commercialize multiple compounds currently in development: isatuximab, an unconjugated anti-CD38 antibody in Phase 3 development for relapsed and refractory multiple myeloma; and ADC’s in earlier phases of development for triple negative breast cancer, solid tumors, and an undisclosed target.
ImmunoGen and Sanofi have also amended a separate 2013 exclusive license to grant Sanofi a fully-paid, exclusive license to develop, manufacture, and commercialize the experimental compound SAR428926, an anti-LAMP1 ADC being studied for the treatment of solid tumors.
As consideration for these amendments, ImmunoGen will receive a $30 million payment and has agreed to forego a limited co-promotion option in the U.S. with respect to the compounds covered by the 2003 agreement, as well as future milestones or royalties under both license agreements. (Source: Immunogen Website)
For more information, visit http://investor.immunogen.com/releasedetail.cfm?ReleaseID=1028202